Articlenpj antimicrobials and resistance2026
Mapping the genomic landscape of antibiotic susceptiblity in Escherichia coli.
Article in npj antimicrobials and resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Antibiotic treatment failure is frequently driven by bacterial insusceptibility, yet understanding of the full repertoire of genes contributing to this in Gram-negative bacteria remains incomplete. We used TraDIS-Xpress, a high-density transposon mutagenesis approach, to systematically define the genetic and physiological determinants of Escherichia coli K-12 susceptibility to 13 antibiotics spanning all major drug classes and multiple concentrations. Beyond known resistance determinants, our data reveal that the E. coli core genome plays a central role in modulating susceptibility. Disruption of metabolic, energy-generating, growth-associated, and amino acid biosynthetic pathways commonly enhanced survival under antibiotic stress, indicating that reduced metabolic activity and growth modulation broadly promote survival during exposure to bactericidal drugs. In contrast, pathways involved in DNA replication, peptidoglycan and lipopolysaccharide synthesis, aminoacyl-tRNA biosynthesis, riboflavin metabolism, and terpenoid backbone biosynthesis consistently aided survival. Experimental validation using defined mutants confirmed that disruption of selected metabolic and respiratory pathways confers survival benefits across multiple antibiotic classes. Together, this work provides a genome-scale framework for understanding antibiotic susceptibility in E. coli, identifies conserved physiological pathways underpinning survival, and offers new opportunities for strategies aimed at reversing insusceptibility and improving antibiotic efficacy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.